Afya Reports Strong Financial Performance for 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy AFYA?
Source: Newsfilter
- Significant Revenue Growth: In 2025, Afya's total revenue reached R$3,697.3 million, reflecting an 11.9% year-over-year increase, with revenue excluding acquisitions growing by 9.2%, indicating strong demand and market share expansion in Brazil's medical education sector.
- Adjusted EBITDA Performance: The adjusted EBITDA for 2025 was R$1,680.3 million, up 15.4% year-over-year, with an adjusted EBITDA margin increasing to 45.4%, demonstrating the company's ongoing improvements in cost control and operational efficiency.
- Substantial Net Income Increase: Afya reported a net income of R$768.4 million for 2025, an 18.4% increase, while adjusted net income grew by 9.9% to R$901.7 million, reflecting robust profitability and financial health.
- Cash Flow and Shareholder Returns: The company achieved a record free cash flow of R$1,056 million in 2025, and the board approved a cash dividend of R$307.4 million, showcasing strong capital allocation and shareholder return capabilities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AFYA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AFYA
Wall Street analysts forecast AFYA stock price to rise
5 Analyst Rating
1 Buy
4 Hold
0 Sell
Hold
Current: 13.880
Low
16.00
Averages
18.90
High
22.00
Current: 13.880
Low
16.00
Averages
18.90
High
22.00
About AFYA
Afya Ltd is a Brazil-based company engaged in the education sector. The Company is mainly focused on operating medical schools, offering health sciences courses, which comprise medicine, dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition and biomedicine. In addition, the Firm provides degree programs and courses in other subjects and disciplines, including undergraduate and post graduate courses in business administration, accounting, law, civil engineering, industrial engineering and pedagogy. The Company's methodological approach combines integrated content, interactive learning, and an adaptive experience for learners. Through its educational content and technology-enabled activities, the Company focuses on personalized learning that mirrors one-on-one tutoring. The Company's undergraduate and graduate campuses are spread across Brazil, as well as its digital medical platform.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Afya Reports Strong Financial Performance for 2025
- Significant Revenue Growth: In 2025, Afya's total revenue reached R$3,697.3 million, reflecting an 11.9% year-over-year increase, with revenue excluding acquisitions growing by 9.2%, indicating strong demand and market share expansion in Brazil's medical education sector.
- Adjusted EBITDA Performance: The adjusted EBITDA for 2025 was R$1,680.3 million, up 15.4% year-over-year, with an adjusted EBITDA margin increasing to 45.4%, demonstrating the company's ongoing improvements in cost control and operational efficiency.
- Substantial Net Income Increase: Afya reported a net income of R$768.4 million for 2025, an 18.4% increase, while adjusted net income grew by 9.9% to R$901.7 million, reflecting robust profitability and financial health.
- Cash Flow and Shareholder Returns: The company achieved a record free cash flow of R$1,056 million in 2025, and the board approved a cash dividend of R$307.4 million, showcasing strong capital allocation and shareholder return capabilities.
See More
Afya Announces R$307.4 Million Cash Dividend Distribution
- Dividend Announcement: Afya's board approved a cash dividend distribution of R$307.4 million, representing 40% of the consolidated net income for 2025, with a dividend per share of R$3.446838, demonstrating the company's strong financial performance and commitment to shareholder returns.
- Payment Arrangement: The dividend will be paid in U.S. dollars on April 6, 2026, with a record date of March 25, 2025, and the payment exchange rate will be determined by the PTAX rate published by the Brazilian Central Bank on March 13, 2026, ensuring stable returns for shareholders.
- Capital Allocation Strategy: CFO Luis Blanco noted that this dividend reflects the company's disciplined approach to capital allocation while continuing to execute approximately 60% of its share repurchase program, expected to be completed by December 2026, further enhancing shareholder returns.
- Long-term Growth Confidence: Afya anticipates distributing 50% of its consolidated net income for 2025, emphasizing the company's confidence in its long-term growth and value creation strategy, and its ongoing commitment to providing substantial returns to shareholders.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, indicating a shift in market sentiment that could influence investor decisions and market trends.
- Upgrades and Downgrades: While specific upgrades and downgrades are not detailed, such changes typically have a direct impact on the stock prices of the affected companies, prompting investors to closely monitor these adjustments to optimize their portfolios.
- Market Reaction Expectations: The adjustments in analysts' ratings may lead to short-term volatility in the stocks involved, and investors should consider these changes as a reference for buying or selling, thereby affecting overall market sentiment.
- Investor Decision Impact: When considering purchasing DG stock, analysts' opinions will serve as a crucial reference for investors, especially in the current market environment where such insights could significantly affect the stock's future performance.
See More
Afya Secures Authorization for 63 Additional Medical Seats
- Seat Increase: Brazil's Ministry of Education has authorized Afya to add 63 medical seats at its Abaetetuba campus, bringing the total to 113 seats, thereby reinforcing its leadership in the Brazilian medical education sector.
- Campus Integration: The non-operational status of Afya Cametá allows for resource consolidation, enabling the Abaetetuba campus to expand its capacity, which optimizes educational resource allocation and enhances overall operational efficiency.
- Market Leadership: This expansion raises Afya's total approved medical seats to 3,766 across its portfolio, highlighting its strong influence and market share in the Brazilian medical education landscape.
- Commitment to Education: Afya's expansion plan not only enhances the quality of medical education but also strengthens its ability to provide comprehensive support to students and physicians, driving overall improvements in healthcare services.
See More
Afya Secures Approval for 63 Additional Medical Seats
- Seat Increase: The Brazilian Ministry of Education has authorized Afya to add 63 medical seats at its Abaetetuba campus, bringing the total to 113, further solidifying its leadership in Brazil's medical education sector.
- Strategic Integration: The non-operational status of Afya Cametá allows for resource optimization, enabling the expansion at Abaetetuba and enhancing overall educational quality.
- Market Leadership: With this expansion, Afya now boasts a total of 3,766 approved medical seats across its portfolio, showcasing its strong influence and growth potential in the Brazilian market.
- Commitment to Education: Afya is dedicated to enhancing the career development of students and physicians through a comprehensive medical education ecosystem, further promoting the delivery of high-quality healthcare services.
See More
Barclays Cuts BJ's Wholesale Price Target to $90
- Price Target Downgrade: Barclays has cut BJ's Wholesale Club's price target from $115 to $90, with analyst Seth Sigman downgrading the stock from Equal-Weight to Underweight, indicating a cautious outlook on the company's future performance.
- Market Reaction: BJ's Wholesale shares closed at $90.88 on Tuesday, nearing the new target price, which reflects the market's sensitivity to analyst rating changes and may impact investor confidence.
- Other Rating Changes: Mizuho slashed OneStream's price target from $25 to $24, downgrading the rating from Outperform to Neutral, suggesting a weakened expectation for the company's future growth.
- Industry Trends: JP Morgan lowered Afya's price target from $24.5 to $22, downgrading the stock from Overweight to Neutral, reflecting concerns about the overall outlook for the education technology sector, which may affect investor sentiment in this field.
See More
Afya Reports Strong Financial Performance for 2025
- Significant Revenue Growth: In 2025, Afya's total revenue reached R$3,697.3 million, reflecting an 11.9% year-over-year increase, with revenue excluding acquisitions growing by 9.2%, indicating strong demand and market share expansion in Brazil's medical education sector.
- Adjusted EBITDA Performance: The adjusted EBITDA for 2025 was R$1,680.3 million, up 15.4% year-over-year, with an adjusted EBITDA margin increasing to 45.4%, demonstrating the company's ongoing improvements in cost control and operational efficiency.
- Substantial Net Income Increase: Afya reported a net income of R$768.4 million for 2025, an 18.4% increase, while adjusted net income grew by 9.9% to R$901.7 million, reflecting robust profitability and financial health.
- Cash Flow and Shareholder Returns: The company achieved a record free cash flow of R$1,056 million in 2025, and the board approved a cash dividend of R$307.4 million, showcasing strong capital allocation and shareholder return capabilities.
See More
Afya Announces R$307.4 Million Cash Dividend Distribution
- Dividend Announcement: Afya's board approved a cash dividend distribution of R$307.4 million, representing 40% of the consolidated net income for 2025, with a dividend per share of R$3.446838, demonstrating the company's strong financial performance and commitment to shareholder returns.
- Payment Arrangement: The dividend will be paid in U.S. dollars on April 6, 2026, with a record date of March 25, 2025, and the payment exchange rate will be determined by the PTAX rate published by the Brazilian Central Bank on March 13, 2026, ensuring stable returns for shareholders.
- Capital Allocation Strategy: CFO Luis Blanco noted that this dividend reflects the company's disciplined approach to capital allocation while continuing to execute approximately 60% of its share repurchase program, expected to be completed by December 2026, further enhancing shareholder returns.
- Long-term Growth Confidence: Afya anticipates distributing 50% of its consolidated net income for 2025, emphasizing the company's confidence in its long-term growth and value creation strategy, and its ongoing commitment to providing substantial returns to shareholders.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, indicating a shift in market sentiment that could influence investor decisions and market trends.
- Upgrades and Downgrades: While specific upgrades and downgrades are not detailed, such changes typically have a direct impact on the stock prices of the affected companies, prompting investors to closely monitor these adjustments to optimize their portfolios.
- Market Reaction Expectations: The adjustments in analysts' ratings may lead to short-term volatility in the stocks involved, and investors should consider these changes as a reference for buying or selling, thereby affecting overall market sentiment.
- Investor Decision Impact: When considering purchasing DG stock, analysts' opinions will serve as a crucial reference for investors, especially in the current market environment where such insights could significantly affect the stock's future performance.
See More
Afya Secures Authorization for 63 Additional Medical Seats
- Seat Increase: Brazil's Ministry of Education has authorized Afya to add 63 medical seats at its Abaetetuba campus, bringing the total to 113 seats, thereby reinforcing its leadership in the Brazilian medical education sector.
- Campus Integration: The non-operational status of Afya Cametá allows for resource consolidation, enabling the Abaetetuba campus to expand its capacity, which optimizes educational resource allocation and enhances overall operational efficiency.
- Market Leadership: This expansion raises Afya's total approved medical seats to 3,766 across its portfolio, highlighting its strong influence and market share in the Brazilian medical education landscape.
- Commitment to Education: Afya's expansion plan not only enhances the quality of medical education but also strengthens its ability to provide comprehensive support to students and physicians, driving overall improvements in healthcare services.
See More
Afya Secures Approval for 63 Additional Medical Seats
- Seat Increase: The Brazilian Ministry of Education has authorized Afya to add 63 medical seats at its Abaetetuba campus, bringing the total to 113, further solidifying its leadership in Brazil's medical education sector.
- Strategic Integration: The non-operational status of Afya Cametá allows for resource optimization, enabling the expansion at Abaetetuba and enhancing overall educational quality.
- Market Leadership: With this expansion, Afya now boasts a total of 3,766 approved medical seats across its portfolio, showcasing its strong influence and growth potential in the Brazilian market.
- Commitment to Education: Afya is dedicated to enhancing the career development of students and physicians through a comprehensive medical education ecosystem, further promoting the delivery of high-quality healthcare services.
See More
Barclays Cuts BJ's Wholesale Price Target to $90
- Price Target Downgrade: Barclays has cut BJ's Wholesale Club's price target from $115 to $90, with analyst Seth Sigman downgrading the stock from Equal-Weight to Underweight, indicating a cautious outlook on the company's future performance.
- Market Reaction: BJ's Wholesale shares closed at $90.88 on Tuesday, nearing the new target price, which reflects the market's sensitivity to analyst rating changes and may impact investor confidence.
- Other Rating Changes: Mizuho slashed OneStream's price target from $25 to $24, downgrading the rating from Outperform to Neutral, suggesting a weakened expectation for the company's future growth.
- Industry Trends: JP Morgan lowered Afya's price target from $24.5 to $22, downgrading the stock from Overweight to Neutral, reflecting concerns about the overall outlook for the education technology sector, which may affect investor sentiment in this field.
See More
